BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/29/2021 2:12:02 AM | Browse: 322 | Download: 596
 |
Received |
|
2021-01-28 14:11 |
|
Peer-Review Started |
|
2021-01-28 14:19 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-03-06 07:06 |
|
Revised |
|
2021-03-19 19:09 |
|
Second Decision |
|
2021-04-19 12:35 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-04-22 03:51 |
|
Articles in Press |
|
2021-04-22 03:51 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-04-27 02:38 |
|
Publish the Manuscript Online |
|
2021-04-29 02:12 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Trond Espen Detlie, Jonas Christoffer Lindstrøm, Marte Eide Jahnsen, Elisabeth Finnes, Heinz Zoller, Bjørn Moum and Jørgen Jahnsen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Trond Espen Detlie, MD, Academic Fellow, Academic Research, Consultant Physician-Scientist, Doctor, Department of Gastroenterology, Akershus University Hospital, Sykehusveien 25, Lørenskog 1478, Norway. t.e.detlie@medisin.uio.no |
| Key Words |
Iron deficiency; Hypophosphatemia; Inflammatory bowel disease; Ferric carboxymaltose; Ferric derisomaltose |
| Core Tip |
High-dose intravenous iron is an effective treatment for iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD). However, ferric carboxymaltose (FCM) is associated with development of hypophosphatemia. This study of adult IBD patients with IDA investigated the mechanisms and clinical manifestations related to hypophosphatemia after treatment of either FCM or ferric derisomaltose (FDI). The incidence of hypophosphatemia was significantly higher after FCM than FDI, and fibroblast growth factor 23 had a key role, inducing loss of phosphate in the urine along with a significant lowering of 1,25-dihydroxyvitamin D and ionised calcium levels. Short-term clinical impact was not demonstrated. |
| Publish Date |
2021-04-29 02:12 |
| Citation |
Detlie TE, Lindstrøm JC, Jahnsen ME, Finnes E, Zoller H, Moum B, Jahnsen J. Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact. World J Gastroenterol 2021; 27(17): 2039-2053 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i17/2039.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i17.2039 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
